Skip to main content
SpringerLink
Log in

Neurologic and Sensory Complications Associated with HSCT

  • Chapter
  • First Online:
Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist

  • 1191 Accesses

Abstract

Severe neurologic complications associated with hematopoietic stem cell transplantation (HSCT) have been reported in approximately 14–25% of all pediatric HSCT patients. The majority of severe neurologic events occur within the first 100 days after HSCT. Risk factors for developing severe neurologic events in the context of HSCT include the age of the HSCT recipient (children <3 years old), underlying disease, prior therapy, conditioning regimen, hematopoietic stem cell (HSC) source, unrelated donor, graft versus host disease (GvHD), immunosuppressive agents, metabolic disorders, and prior central nervous system (CNS) infections. The most common causes of developing a severe neurologic complication are medications (particularly calcineurin inhibitors), radiation-induced, hemorrhage-related, immune-mediated, and infection-induced. The most common severe neurologic events are seizures, cerebral vascular events as well as change in consciousness (mental status changes), and encephalopathy/leukoencephalopathy. Severe neurologic events account for 10–15% of all deaths in HSCT patients. Sensory complications such as radiation-induced cataracts, platinum-induced high-frequency hearing loss, and high-dose chemotherapy-induced taste dysfunction are seen quite often in pediatric HSCT recipients. Because pediatric HSCT recipients are still developing, effort needs to be made to minimize neurologic and sensory complications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Kang JM, Kim YJ, Kim JY, Cho EJ, Lee JH, Lee MH, et al. Neurologic complications after allogeneic hematopoietic stem cell transplantation in children: analysis of prognostic factors. Biol Blood Marrow Transplant. 2015;21(6):1091–8

    Article  PubMed  Google Scholar 

  2. Weber C, Schaper J, Tibussek D, Adams O, MacKenzie CR, Dilloo D, et al. Diagnostic and therapeutic implications of neurological complications following paediatric haematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;41(3):253–9

    Article  PubMed  Google Scholar 

  3. Uckan D, Cetin M, Yigitkanli I, Tezcan I, Tuncer M, Karasimav D, et al. Life-threatening neurological complications after bone marrow transplantation in children. Bone Marrow Transplant. 2005;35(1):71–6

    Article  CAS  PubMed  Google Scholar 

  4. Maffini E, Festuccia M, Brunello L, Boccadoro M, Giaccone L, Bruno B. Neurologic complications after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(3):388–97

    Article  PubMed  Google Scholar 

  5. Faraci M, Lanino E, Dini G, Fondelli MP, Morreale G, Dallorso S, et al. Severe neurologic complications after hematopoietic stem cell transplantation in children. Neurology. 2002;59(12):1895–904

    Article  CAS  PubMed  Google Scholar 

  6. Schmidt K, Schulz AS, Debatin KM, Friedrich W, Classen CF. CNS complications in children receiving chemotherapy or hematopoietic stem cell transplantation: retrospective analysis and clinical study of survivors. Pediatr Blood Cancer. 2008;50(2):331–6

    Article  PubMed  Google Scholar 

  7. Panosyan EH, Ikeda AK, Chang VY, Laks DR, Reeb CL, Bowles LV, et al. High-dose chemotherapy with autologous hematopoietic stem-cell rescue for pediatric brain tumor patients: a single institution experience from UCLA. J Transp Secur. 2011;2011:740673

    Google Scholar 

  8. Shenoy S, Eapen M, Panepinto JA, Logan BR, Wu J, Abraham A, et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016;128(21):2561–7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Walters MC, Sullivan KM, Bernaudin F, Souillet G, Vannier JP, Johnson FL, et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood. 1995;85(4):879–84

    CAS  PubMed  Google Scholar 

  10. Woodard P, Helton KJ, Khan RB, Hale GA, Phipps S, Wang W, et al. Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease. Br J Haematol. 2005;129(4):550–2

    Article  PubMed  Google Scholar 

  11. Boelens JJ, Orchard PJ, Wynn RF. Transplantation in inborn errors of metabolism: current considerations and future perspectives. Br J Haematol. 2014;167(3):293–303

    Article  PubMed  Google Scholar 

  12. Pruitt AA, Graus F, Rosenfeld MR. Neurological complications of transplantation: part I: hematopoietic cell transplantation. Neurohospitalist. 2013;3(1):24–38

    Article  PubMed  PubMed Central  Google Scholar 

  13. Siegal D, Keller A, Xu W, Bhuta S, Kim DH, Kuruvilla J, et al. Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol Blood Marrow Transplant. 2007;13(11):1369–79

    Article  PubMed  Google Scholar 

  14. Iguchi A, Kobayashi R, Yoshida M, Kaneda M, Watanabe N, Cho Y, et al. Neurological complications after stem cell transplantation in childhood. Bone Marrow Transplant. 1999;24(6):647–52

    Article  CAS  PubMed  Google Scholar 

  15. Caselli D, Rosati A, Faraci M, Podda M, Ripaldi M, Longoni D, et al. Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(2):282–5

    Article  CAS  PubMed  Google Scholar 

  16. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990;50(19):6203–7

    CAS  PubMed  Google Scholar 

  17. Soni S, Skeens M, Termuhlen AM, Bajwa RP, Gross TG, Pai V. Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2012;59(4):762–4

    Article  PubMed  Google Scholar 

  18. Beitinjaneh A, McKinney AM, Cao Q, Weisdorf DJ. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(3):300–8

    Article  CAS  PubMed  Google Scholar 

  19. Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales—a report from the Children’s Oncology Group. J Clin Oncol. 2014;32(6):527–34

    Article  PubMed  PubMed Central  Google Scholar 

  20. Punnett A, Bliss B, Dupuis LL, Abdolell M, Doyle J, Sung L. Ototoxicity following pediatric hematopoietic stem cell transplantation: a prospective cohort study. Pediatr Blood Cancer. 2004;42(7):598–603

    Article  PubMed  Google Scholar 

  21. Faraci M, Bekassy AN, De Fazio V, Tichelli A, Dini G, Paediatric E, et al. Non-endocrine late complications in children after allogeneic haematopoietic SCT. Bone Marrow Transplant. 2008;41(Suppl 2):S49–57

    Article  CAS  PubMed  Google Scholar 

  22. Cordelli DM, Masetti R, Zama D, Gueraldi D, Rondelli R, Cottone C, et al. Etiology, characteristics and outcome of seizures after pediatric hematopoietic stem cell transplantation. Seizure. 2014;23(2):140–5

    Article  PubMed  Google Scholar 

  23. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500

    Article  CAS  PubMed  Google Scholar 

  24. Masetti R, Cordelli DM, Zama D, Vendemini F, Biagi C, Franzoni E, et al. PRES in children undergoing hematopoietic stem cell or solid organ transplantation. Pediatrics. 2015;135(5):890–901

    Article  PubMed  Google Scholar 

  25. Zama D, Masetti R, Cordelli DM, Vendemini F, Giordano L, Milito G, et al. Risk factor analysis of posterior reversible encephalopathy syndrome after allogeneic hematopoietic SCT in children. Bone Marrow Transplant. 2014;49(12):1538–40

    Article  CAS  PubMed  Google Scholar 

  26. Moskowitz A, Nolan C, Lis E, Castro-Malaspina H, Perales MA. Posterior reversible encephalopathy syndrome due to sirolimus. Bone Marrow Transplant. 2007;39(10):653–4

    Article  CAS  PubMed  Google Scholar 

  27. Dicuonzo F, Salvati A, Palma M, Lefons V, Lasalandra G, De Leonardis F, et al. Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings. J Child Neurol. 2009;24(8):1013–8

    Article  PubMed  Google Scholar 

  28. Zamvar V, Puntis JW. Re: “Posterior reversible encephalopathy syndrome following infliximab infusion”. J Pediatr Gastroenterol Nutr. 2010;50(3):353

    Article  PubMed  Google Scholar 

  29. Zito JA, Lee CC, Johnson S, Singer A, Vacirca J. Reversible posterior leukoencephalopathy syndrome after rituximab. Am J Emerg Med. 2010;28(4):537.e1–2

    Article  Google Scholar 

  30. Yoshida S, Hayakawa K, Yamamoto A, Kuroda H, Imashuku S. The central nervous system complications of bone marrow transplantation in children. Eur Radiol. 2008;18(10):2048–59

    Article  PubMed  Google Scholar 

  31. Uderzo C, Bonanomi S, Busca A, Renoldi M, Ferrari P, Iacobelli M, et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation. 2006;82(5):638–44

    Article  PubMed  Google Scholar 

  32. Phipps S, Rai SN, Leung WH, Lensing S, Dunavant M. Cognitive and academic consequences of stem-cell transplantation in children. J Clin Oncol. 2008;26(12):2027–33

    Article  PubMed  Google Scholar 

  33. Willard VW, Leung W, Huang Q, Zhang H, Phipps S. Cognitive outcome after pediatric stem-cell transplantation: impact of age and total-body irradiation. J Clin Oncol. 2014;32(35):3982–8

    Article  PubMed  PubMed Central  Google Scholar 

  34. Gurney JG, Ness KK, Rosenthal J, Forman SJ, Bhatia S, Baker KS. Visual, auditory, sensory, and motor impairments in long-term survivors of hematopoietic stem cell transplantation performed in childhood: results from the Bone Marrow Transplant Survivor study. Cancer. 2006;106(6):1402–8

    Article  PubMed  Google Scholar 

  35. Freyer DR, Chen L, Krailo MD, Knight K, Villaluna D, Bliss B, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(1):63–74

    Article  CAS  PubMed  Google Scholar 

  36. Suh DW, Ruttum MS, Stuckenschneider BJ, Mieler WF, Kivlin JD. Ocular findings after bone marrow transplantation in a pediatric population. Ophthalmology. 1999;106(8):1564–70

    Article  CAS  PubMed  Google Scholar 

  37. Kalinina Ayuso V, Hettinga Y, van der Does P, Boelens JJ, Rothova A, de Boer J. Ocular complications in children within 1 year after hematopoietic stem cell transplantation. JAMA Ophthalmol. 2013;131(4):470–5

    Article  PubMed  Google Scholar 

  38. van Kempen-Harteveld ML, van Weel-Sipman MH, Emmens C, Noordijk EM, van der Tweel I, Revesz T, et al. Eye shielding during total body irradiation for bone marrow transplantation in children transplanted for a hematological disorder: risks and benefits. Bone Marrow Transplant. 2003;31(12):1151–6

    Article  PubMed  Google Scholar 

  39. Majorana A, Amadori F, Bardellini E, Campus G, Conti G, Strohmenger L, et al. Taste dysfunction in patients undergoing hematopoietic stem cell transplantation: clinical evaluation in children. Pediatr Transplant. 2015;19(5):571–5

    Article  PubMed  Google Scholar 

  40. Comeau TB, Epstein JB, Migas C. Taste and smell dysfunction in patients receiving chemotherapy: a review of current knowledge. Support Care Cancer. 2001;9(8):575–80

    Article  CAS  PubMed  Google Scholar 

  41. Mattsson T, Arvidson K, Heimdahl A, Ljungman P, Dahllof G, Ringden O. Alterations in taste acuity associated with allogeneic bone marrow transplantation. J Oral Pathol Med. 1992;21(1):33–7

    Article  CAS  PubMed  Google Scholar 

  42. Boer CC, Correa ME, Miranda EC, de Souza CA. Taste disorders and oral evaluation in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant. 2010;45(4):705–11

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Oncology/Hematology, Penn State Health Children’s Hospital and Penn State Cancer Institute at the Penn State Milton S. Hershey Medical Center, 500 University Dr., P.O. Box 850, MC H085, Hershey, PA, 17033-0850, USA

    Valerie I. Brown MD, PhD

Authors
  1. Valerie I. Brown MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valerie I. Brown MD, PhD .

Editor information

Editors and Affiliations

  1. Division of Pediatric Oncology/Hematology, Penn State Health Children’s Hospital and Penn State Cancer Institute at the Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA

    Valerie I. Brown

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Brown, V.I. (2018). Neurologic and Sensory Complications Associated with HSCT. In: Brown, V. (eds) Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. Springer, Cham. https://doi.org/10.1007/978-3-319-63146-2_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-63146-2_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-63144-8

  • Online ISBN: 978-3-319-63146-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation